Grammatical mood

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

Retrieved on: 
Thursday, December 14, 2023
Walking, Pregnancy, Theft, PPD, Risk, Vitamin, Benzodiazepine, Breast milk, Tell, CIV, Woman, Grammatical mood, OBGYN, Medical research, Hope, Biogen, Capsule, BIIB, Health, Physician, Alertness, Sage, Therapy, Dizziness, Mental health, Behavior, Insurance, Confusion, CNS, Pharmacy, Medicaid, Patient, Diagnosis, Central nervous system, Somnolence, Pharmaceutical industry

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced ZURZUVAE™ (zuranolone) 50 mg (two 25 mg capsules per day) CIV is now available by prescription for the treatment of postpartum depression (PPD) for adults in the United States, with product already at specialty pharmacies and delivered to patients. ZURZUVAE is the first and only oral, 14-day treatment course for adults with PPD that can provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3.

Key Points: 
  • “For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.
  • The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients.
  • The companies are partnering with several of the leading national specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment.
  • ZURZUVAE is not for use in children
    How can I watch for and try to prevent suicidal thoughts and actions?

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Psychiatry, Quality of life, Medication discontinuation, GEMINI, Evolve, Depression, University, DSM-IV codes, Therapy, Drug, Quality, FRCPC, Annual general meeting, CNS, American College, University of Toronto, EVOLVE, Central nervous system, MDD, Anxiety, Grammatical mood, ASCEND, Pharmaceutical industry

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD). These new data were presented at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting, held in Tampa, Florida, from Dec. 3-6, 2023.

Key Points: 
  • New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode
    NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD).
  • These new data were presented at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting, held in Tampa, Florida, from Dec. 3-6, 2023.
  • An evaluation of interest and activity levels of individuals with MDD following treatment with Auvelity in a pooled post-hoc analysis of the placebo-controlled GEMINI and active-controlled ASCEND studies, and an analysis of potential withdrawal symptoms following discontinuation of Auvelity treatment in the GEMINI trial were also presented.
  • “Depression exacts an extraordinary impact on affected individuals especially by impairing enjoyment in activities and role function,” said Roger McIntyre, MD, FRCPC, Professor of Psychiatry and Pharmacology at the University of Toronto and lead author.

Brain Fitness is Among Fastest-Growing Medicare Advantage Benefits for 2024

Retrieved on: 
Tuesday, December 5, 2023
Quality of life, Exercise, Cognition, Attention, S.H.I.E.L.D., Faegre Drinker, Grammatical mood, Health, Incidence, SAN, Hearing, AARP, Nature, Medicare, Growth, Memory, Healthcare industry, Physical fitness, CMS, Health insurance

SAN FRANCISCO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- An analysis of new data for 2024 from the Centers for Medicare and Medicaid Services (CMS) reveals that “memory fitness” supplemental benefits (often called “brain exercises”) have become one of the most popular offerings in the increasingly competitive Medicare Advantage market.

Key Points: 
  • SAN FRANCISCO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- An analysis of new data for 2024 from the Centers for Medicare and Medicaid Services (CMS) reveals that “memory fitness” supplemental benefits (often called “brain exercises”) have become one of the most popular offerings in the increasingly competitive Medicare Advantage market.
  • San Francisco-based Posit Science reports that its BrainHQ brain exercise app is the memory fitness benefit selected by the most Medicare Advantage organizations (MAOs), with a reach that has grown more than ten-fold in the past four years.
  • Medicare Advantage (MA), the managed care insurance plans offered by non-profit and for-profit corporations as an alternative to traditional Medicare, has grown to over 30 million members — more than half of the Medicare market.
  • The growth in MA has been fueled by low (often zero dollar) monthly premiums, as well as by offering supplemental benefits not covered by traditional Medicare.

Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting

Retrieved on: 
Tuesday, December 5, 2023
Neuropsychiatry, Treatment, DSM-IV codes, IND, Grammatical mood, Depression, Prevalence, Literature, Mouse, Human, DSM-5, Cyclothymia, MADRS, Anxiety, Prefrontal cortex, Hallucination, Annual general meeting, Clinical Global Impression, CNS, Social, Poster, American College, Restless, Central nervous system, MDD, Patient, Therapy, Lumateperone, Pharmaceutical industry

NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the American College of Neuropsychopharmacology (ACNP) 62nd Annual Meeting.

Key Points: 
  • Company presents preclinical data on ITI-1549, our lead product candidate in our non-hallucinogenic psychedelics program in mood disorders and other psychiatric disorders.
  • NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the American College of Neuropsychopharmacology (ACNP) 62nd Annual Meeting.
  • Inner tension is an item within the MADRS which is often used as a surrogate marker for anxiety.
  • The data presented in this poster represent further analyses from Study 403.

A Story Of Perseverance, Faith, and Triumph Over Circumstances: How Iran Amandah Went From A 45-Year Prison Sentence To Wall Street’s Spotlight

Retrieved on: 
Tuesday, December 5, 2023
Dark, Grammatical mood, Social media, Second, Darkness, Book, Survival, Knowledge, Amazon (company), Redemption

For Iran D. Amandah, the gripping journey from hopelessness to unparalleled success came amid the harsh realities of prison life.

Key Points: 
  • For Iran D. Amandah, the gripping journey from hopelessness to unparalleled success came amid the harsh realities of prison life.
  • Dark.
  • It’s a story about a man who, against all odds, chose to bring change not just for himself but for an entire community.
  • Iran discovered and pursued an unquenchable thirst for knowledge and relentlessly sculpted a vision for his future.

Studies: Promising Cognitive and Imaging Results in Alzheimer’s and pre-dementia Patients

Retrieved on: 
Tuesday, November 21, 2023
Quality of life, Clutch (eggs), Cognition, Dementia, Attention, Medicine, Grammatical mood, Diet, White matter, Systems biology, Incidence, SAN, Recode, JAD, University, San Francisco Bay Area, Medicare, Worldwide, Bangladesh Technical Education Board, Patient, Memory, Curriculum, Journal, Hearing, Exercise

Overall, the researchers saw significant and widespread improvement in cognitive performance as measured by MoCA scores, which improved in 76% of patients and CNS-Vital Signs scores, which improved in 84% of patients.

Key Points: 
  • Overall, the researchers saw significant and widespread improvement in cognitive performance as measured by MoCA scores, which improved in 76% of patients and CNS-Vital Signs scores, which improved in 84% of patients.
  • They also saw physical brain improvements in the imaging results that showed a trend toward renormalization to results typically seen in healthy older adults.
  • While the imaging results appear to correspond with the cognitive assessment results, due to the small sample size and correction for multiple comparisons, the imaging results were not significant.
  • “These are promising and exciting results,” said Dr. Henry Mahncke , CEO of Posit Science.

The SOGC will be holding the Menopause Summit 2.0 at this year’s Ontario CME in Toronto, November 24th

Retrieved on: 
Monday, November 20, 2023
Survivor, Woman, Breast cancer, Grammatical mood, Research, CME, Menopause, Health, Brain, GSM, Internet, Anxiety, Workplace, Knowledge, Ageing, Social media, ADHD, Birth control

TORONTO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- The SOGC is proud to be presenting our Menopause Summit 2.0 at this year’s Ontario CME from November 23-25.

Key Points: 
  • TORONTO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- The SOGC is proud to be presenting our Menopause Summit 2.0 at this year’s Ontario CME from November 23-25.
  • “As one of relatively few menopause specialists in the country, I am bursting with pride and excitement to be hosting our second menopause summit of the year with the support of the SOGC.
  • I am immensely looking forward to celebrating menopause and aging women with my colleagues at this week’s event,” said Dr. Michelle Jacobson, Chair of Menopause Summit 2.0.
  • How to identify symptoms and formulate alterations that can improve work-life experience for those going through menopause.

HedoniaUSA Inc. Selects Dolphin Entertainment As Its Communications Agency of Record

Retrieved on: 
Thursday, December 21, 2023
Marketing, Partnership, Grammatical mood, Dolphin Entertainment, Dolphin, Executive Committee, Growth, Internet

BETHESDA, Md., Dec. 21, 2023 /PRNewswire/ -- HedoniaUSA Inc., a new mental fitness and wellness company, today proudly announced its strategic partnership with Dolphin Entertainment (NASDAQ:DLPN), a leader in lifestyle earned media and in-culture marketing, as its agency of record. This collaboration marks a significant milestone in HedoniaUSA's commitment to elevating its brand presence and market positioning by partnering with a known leader in integrated marketing and media relations.

Key Points: 
  • Dolphin Entertainment's roster of agencies will develop and execute comprehensive marketing and communication initiatives.
  • As the communications agency of record, Dolphin Entertainment will leverage its creative prowess to amplify HedoniaUSA's brand messages and educate and engage national audiences who currently have or are being treated for depressive symptoms.
  • "We are thrilled to join forces with Dolphin Entertainment as our communications agency of record," said Dany Sfeir , CEO at HedoniaUSA.
  • "Partnering with HedoniaUSA presents an exciting opportunity to showcase our capabilities in driving brand success," stated Charlie Dougiello, Chief Innovation Officer, Executive Committee at Dolphin.

New Study Reveals Coaching Has Clinically Meaningful Impact on Pediatric Mental Health

Retrieved on: 
Monday, December 18, 2023
Research, Depression, Anxiety, Mental health, Psychiatry, Mental, Grammatical mood

MADISON, Wis., Dec. 18, 2023 /PRNewswire/ -- Bend Health, Inc. ("Bend"), a national provider of pediatric mental health care for children, teens, and families, today announced the findings of a new study highlighting the positive impact of online coaching sessions on anxiety and depression in youth. Published in JMIR Formative Research, the findings show substantial improvements in mental health symptoms of participants after just a few online coaching sessions.

Key Points: 
  • Published in J MIR Formative Research , the findings show substantial improvements in mental health symptoms of participants after just a few online coaching sessions.
  • "These new study findings highlight the positive impact of coaching as a modality for reaching the millions of kids who need mental health support.
  • One in five young people do not receive adequate mental health treatment, highlighting a crucial need for greater accessibility in pediatric mental health services.
  • Bend Health is committed to providing accessible and effective mental health care to positively impact the lives of young people.

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression

Retrieved on: 
Monday, November 13, 2023
Safety, Incidence, Grammatical mood, Dissociative, Plasma, Headache, Patient, Male, FDA, Treatment-resistant depression, MADRS, TRD, Czech Republic, Esketamine, Ketamine, Dizziness, Pharmaceutical industry, Dietary supplement, Boston

MUNICH, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today favorable results from its head-to-head trial with KET01, the Company’s proprietary lead asset, versus SPRAVATO®, the FDA-approved intranasal spray for patients with Treatment-Resistant Depression (TRD). KET01 is an IP protected oral prolonged-release formulation of ketamine and is being studied in patients with TRD. Due to its unique metabolite profile, the incidence of dissociation with KET01 was very low and statistically significantly lower relative to SPRAVATO®, pointing to a clinically meaningful difference, which could offer the potential for a safe at-home unsupervised administration. During the summer Ketabon also released data from its Phase 2 KET01-02 trial with KET01, which demonstrated rapid and durable improvements in depressive symptoms in TRD. 

Key Points: 
  • KET01 is an IP protected oral prolonged-release formulation of ketamine and is being studied in patients with TRD.
  • During the summer Ketabon also released data from its Phase 2 KET01-02 trial with KET01, which demonstrated rapid and durable improvements in depressive symptoms in TRD.
  • Only minimal signs of dissociative symptoms were detected by the CADSS scale, and no changes in cardiovascular parameters were detected.
  • “Data continues to suggest rapid and clinically relevant reduction of depressive symptoms after oral treatment with 240 mg/day of KET01.